You are here: Industry Insights > AI

News List

Pharnext, UHI to Evaluate Repurposed Drugs Against COVID-19 contractpharma
April 23, 2020
Aims to rapidly test several approved drugs as potential candidates for fighting COVID-19 using big data and artificial intelligence.
Insilico and Boehringer to use AI for drug targets discovery pharmaceutical-technology
April 16, 2020
Boehringer partners Insilico for AI-based discovery of drug targets. Insilico Medicine has partnered with Boehringer Ingelheim.
Experimental AI tool predicts which COVID-19 patients develop respiratory disease worldpharmanews
March 31, 2020
An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study found.
XtalPi Collaborates with Porton contractpharma
March 13, 2020
Combining AI algorithms with targeted experiments to solve bottleneck challenges in drug development.
Iktos and SRI to use AI for Covid-19 drug development pharmaceutical-technology
March 05, 2020
Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza.
AI Might Help Spot, Evaluate Prostate Cancer drugs
January 17, 2020
In another step toward using artificial intelligence in medicine, a new study shows that computers can be trained to match human experts in judging the severity of prostate tumors.
BioMotiv and Atomwise sign AI partnership to transform therapeutic development pharmaceutical-business-review
January 17, 2020
BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, announced a strategic collaboration to co-develop therapies.
AI System Can Detect, Grade Cancer in Prostate Needle Biopsy drugs
January 16, 2020
An artificial intelligence (AI) system can be used to detect and grade prostate cancer in prostate needle biopsy samples, according to a study published online January in The Lancet Oncology.
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery worldpharmanews
January 14, 2020
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration.
Funding for AI in drug development, clinical trials and information synthesis hits $5.2bn europeanpharmaceuticalreview
January 09, 2020
A study has suggested that while funding for artificial intelligence in pharma was $5.2bn in 2019, overall investment is slowing.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 18 19 Next page